The introduction of popular weight-loss medications in India last year has not only prompted a significant surge in consumer demand but also led to a remarkable increase in public discourse surrounding obesity. From conversations led by celebrities to multiple influencer posts and widespread “disease awareness” initiatives across digital platforms, the focus on weight management has heightened considerably.

However, India’s drug regulatory authority has expressed concerns that these extensive promotional efforts could be influencing public perceptions in unintended ways. In an advisory released on March 10, the Central Drugs Standard Control Organisation (CDSCO) cautioned pharmaceutical companies against any form of advertising for prescription-only medications directed at the general public.

New Drug Launches Prompt Concerns

This advisory is set against the backdrop of high-profile anti-obesity medications being marketed in India by international pharmaceutical firms. Notably, Eli Lilly and Company launched Mounjaro, which quickly ascended to become one of the top-selling drugs in the country shortly after its release.

Likewise, Novo Nordisk introduced its well-recognized medications, Wegovy and Ozempic, to the Indian market last year. While both companies have framed their outreach as initiatives aimed at enhancing understanding of obesity as a chronic condition, healthcare experts argue that the boundary between public education and advertising is becoming increasingly blurred.

Public Health Concerns Raised

Health specialists emphasize that disease-awareness initiatives, if not adequately monitored, could effectively function as indirect marketing tools. Dr. Rajiv Kovil, a diabetologist based in Mumbai, highlighted that such campaigns often shift public opinion toward pharmaceutical interventions.

He noted that while awareness campaigns are valuable, those aligned primarily with pharmaceutical interests risk conflating public health messaging with commercial expansion. This could unwittingly portray medication as the primary avenue for obesity management, even as more comprehensive approaches may be necessary.

Risks of Misuse and Expectations

India grapples with a significant obesity crisis, with estimates indicating approximately 254 million individuals suffering from general obesity and another 351 million experiencing abdominal obesity, a significant risk factor for various chronic diseases. Given this context, healthcare experts have expressed concerns about the potential ramifications of aggressive marketing strategies tied to new medications.

Dr. Santanu Tripathi, a senior pharmacologist, noted a shift in pharma marketing strategies in India, transitioning from targeting healthcare professionals to reaching prospective patients directly. Even without explicitly naming products, such messaging can still trigger brand awareness and affect consumer perceptions.

CDSCO Advisory Details

The advisory from CDSCO emphasizes that medications, including GLP-1 receptor agonists, should only be prescribed by registered medical professionals for validated medical purposes. It warns against any promotional messaging that exaggerates benefits, claims guaranteed weight loss, or diminishes the significance of lifestyle changes such as diet and exercise.

The regulator specifically cautioned against surrogate marketing techniques, including disease-awareness initiatives and influencer collaborations, that indirectly promote prescription drugs and bolster brand recognition among the public. The advisory underscores that obesity management should be recognized as a chronic condition necessitating comprehensive care, with pharmacological treatments framed within the context of broader public health strategies.

Need for Regulatory Enforcement

Despite the issuance of this warning, some experts argue that the regulatory body must take additional steps beyond simply providing advisories to effect meaningful change in marketing practices. Dr. Tripathi stressed the importance of ongoing monitoring and enforcement.

He asserted that while the advisory represents an essential initial measure, the regulatory agency’s role must extend beyond this point to ensure that messaging does not disproportionately encourage drug-based solutions. Failure to implement adequate safeguards may necessitate more stringent regulatory interventions.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share